Show simple item record

dc.contributor.authorPopovici, Jean
dc.contributor.authorTebben, Kieran
dc.contributor.authorWitkowski, Benoit
dc.contributor.authorSerre, David
dc.date.accessioned2021-02-19T18:31:19Z
dc.date.available2021-02-19T18:31:19Z
dc.date.issued2021-01-24
dc.identifier.urihttp://hdl.handle.net/10713/14730
dc.description.abstractPlasmodium vivax radical cure requires the administration of a blood schizonticide for killing blood-stage parasites and the addition of a drug able to kill hypnozoites, the dormant parasite stages residing in the liver of infected patients. All drugs used clinically for killing hypnozoites are 8-aminoquinolines and among them, primaquine has been at the forefront of P. vivax case management for decades. We discuss here the possible factors that could lead to the emergence and selection of P. vivax primaquine resistant parasites and emphasize on how a better understanding of the mechanisms underlying primaquine treatment and hypnozoite biology is needed to prevent this catastrophic scenario from happening. © 2021 The Authorsen_US
dc.description.urihttps://doi.org/10.1016/j.ijpddr.2020.12.004en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofInternational Journal for Parasitology. Drugs and Drug Resistanceen_US
dc.rightsCopyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.en_US
dc.subject.meshPrimaquineen_US
dc.subject.meshPlasmodium vivaxen_US
dc.subject.mesh8-aminoquinolineen_US
dc.subject.meshAntiprotozoal Agentsen_US
dc.subject.meshParasitesen_US
dc.titlePrimaquine for Plasmodium vivax radical cure: What we do not know and why it matters.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijpddr.2020.12.004
dc.identifier.pmid33529838
dc.source.volume15
dc.source.beginpage36
dc.source.endpage42
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record